Response to rituximab: has the original hypothesis been confirmed?

Before the use of rituximab, the strongest accepted evidence for an association between B-cells and rheumatoid arthritis (RA) was that clinical disease was associated with serum autoantibodies. The ability to remove B-cells with rituximab has also revealed the relative importance of the different immunological parameters that underlie the clinical symptoms of RA. Geraldine Cambridge, also known as Jo Cambridge, is Principal Research Fellow, Inflammation, Division of Medicine, Faculty of Medical Sciences, University College London in the United Kingdom.

Publication

 

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
Guest visitors to the Faculti website can view any insight monthly. You have insight(s) remaining for this month or Register for free as an individual and view thousands of insights in our archive today or subscribe for subject access.

You may already have unlimited institutional access to Faculti. Many colleges and universities have institutional memberships. If you are affiliated with a subscribing institution, please access this site through your SSO/EZproxy/IP address. This should permit you with unlimited views. However, you will not be able to view non-subscribed to content.

Copyright © Faculti Media Limited 2022. All rights reserved.
error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×